We are live on ! Find out more
SPRO icon

Spero Therapeutics

54 hedge funds and large institutions have $17.2M invested in Spero Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

0.41% less ownership

Funds ownership: 27.32%26.91% (-0.41%)

4% less funds holding

Funds holding: 5654 (-2)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

18% less capital invested

Capital invested by funds: $20.8M → $17.2M (-$3.66M)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $73K

Holders
54
Holders Change
-2
Holders Change %
-3.57%
% of All Funds
0.86%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
5
Increased
12
Reduced
14
Closed
7
Calls
Puts
$73K
Net Calls
-$73K
Net Calls Change
+$81K
Name Holding Trade Value Shares
Change
Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$117 -$2.9K -2,092 -96%
BNP Paribas Financial Markets
52
BNP Paribas Financial Markets
France
$15 +$17 +12 New
Qube Research & Technologies (QRT)
53
Qube Research & Technologies (QRT)
United Kingdom
$1 +$1 +1 New
RA
54
Royce & Associates
New York
-$33.1K -22,851 Closed
VF
55
Virtu Financial
New York
-$32K -22,195 Closed
Citadel Advisors
56
Citadel Advisors
Florida
-$21.7K -14,956 Closed
Federated Hermes
57
Federated Hermes
Pennsylvania
-$3.84K -2,647 Closed
Simplex Trading
58
Simplex Trading
Illinois
-$3.16K -2,281 Closed
IRC
59
Investors Research Corp
Georgia
-$73 -50 Closed
Fidelity Investments
60
Fidelity Investments
Massachusetts
-$6 -4 Closed
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
+$416 +300 New

SPRO Hedge Fund Activity: Q3 2023 in Review

54 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q3 2023, worth a combined $17.2M — down 18% from $20.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SPRO and 5 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 12 added.

The largest buyer was Anson Funds Management, adding an estimated $990K. The largest seller was Rock Springs Capital Management, cutting an estimated $848K.

  • 54 institutional investors held Spero Therapeutics (SPRO) as of Q3 2023, down from 56 in Q2 2023.
  • Funds reported $17.2M of Spero Therapeutics stock for Q3 2023, down 18% quarter-over-quarter.
  • 5 funds opened new Spero Therapeutics positions in Q3 2023 and 7 closed out, a net change of -2 holders.
  • The largest Spero Therapeutics buyer in Q3 2023 was Anson Funds Management, an estimated $990K added.
  • The largest Spero Therapeutics seller in Q3 2023 was Rock Springs Capital Management, an estimated $848K sold.

Based on aggregated 13F filings for Q3 2023.